430 related articles for article (PubMed ID: 18030652)
21. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
22. Recent and remote memory dissociation: medication effects and hippocampal function in schizophrenia.
Gilbertson MW; van Kammen DP
Biol Psychiatry; 1997 Oct; 42(7):585-95. PubMed ID: 9376455
[TBL] [Abstract][Full Text] [Related]
23. [Double-blind comparison of 3 x 75 mg zotepine und 3 x 4 mg haloperidol in acute schizophrenic patients].
Klieser E; Lehmann E; Tegeler J
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():14-7. PubMed ID: 1683333
[TBL] [Abstract][Full Text] [Related]
24. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia.
Rémillard S; Pourcher E; Cohen H
J Int Neuropsychol Soc; 2008 Jan; 14(1):110-8. PubMed ID: 18078537
[TBL] [Abstract][Full Text] [Related]
25. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
Velligan DI; Miller AL
J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
[TBL] [Abstract][Full Text] [Related]
26. FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia.
Buchsbaum MS; Haznedar M; Newmark RE; Chu KW; Dusi N; Entis JJ; Goldstein KE; Goodman CR; Gupta A; Hazlett E; Iannuzzi J; Torosjan Y; Zhang J; Wolkin A
Schizophr Res; 2009 Oct; 114(1-3):161-71. PubMed ID: 19695836
[TBL] [Abstract][Full Text] [Related]
27. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
Piskulić D; Olver JS; Maruff P; Norman TR
Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
[TBL] [Abstract][Full Text] [Related]
28. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
29. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
Mishara AL; Goldberg TE
Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
[TBL] [Abstract][Full Text] [Related]
30. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
Reschke RW
Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
[TBL] [Abstract][Full Text] [Related]
31. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
[TBL] [Abstract][Full Text] [Related]
32. HTTLPR functional polymorphism in schizophrenia: executive functions vs. sustained attention dissociation.
Bosia M; Anselmetti S; Pirovano A; Ermoli E; Marino E; Bramanti P; Smeraldi E; Cavallaro R
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):81-5. PubMed ID: 19818823
[TBL] [Abstract][Full Text] [Related]
33. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
Krivoy A; Weizman A; Laor L; Hellinger N; Zemishlany Z; Fischel T
Eur Neuropsychopharmacol; 2008 Feb; 18(2):117-21. PubMed ID: 17728110
[TBL] [Abstract][Full Text] [Related]
34. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
[TBL] [Abstract][Full Text] [Related]
35. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
Kawai N; Yamakawa Y; Baba A; Nemoto K; Tachikawa H; Hori T; Asada T; Iidaka T
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1009-14. PubMed ID: 16644082
[TBL] [Abstract][Full Text] [Related]
36. Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.
Kim JH; Byun HJ
J Clin Pharm Ther; 2007 Oct; 32(5):461-7. PubMed ID: 17875112
[TBL] [Abstract][Full Text] [Related]
37. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
[TBL] [Abstract][Full Text] [Related]
38. The European Post-marketing Observational Serdolect (EPOS) Project: increasing our understanding of schizophrenia therapy.
Wehnert A
Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S27-30. PubMed ID: 9690967
[TBL] [Abstract][Full Text] [Related]
39. Sertindole for the treatment of schizophrenia.
Azorin JM; Kaladjian A; Fakra E; Adida M
Expert Opin Pharmacother; 2010 Dec; 11(18):3053-64. PubMed ID: 21080854
[TBL] [Abstract][Full Text] [Related]
40. Drug safety and efficacy evaluation of sertindole for schizophrenia.
Karamatskos E; Lambert M; Mulert C; Naber D
Expert Opin Drug Saf; 2012 Nov; 11(6):1047-62. PubMed ID: 22992213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
